APA (7th ed.) Citation

FG, U., C, S., T, P., T, H., M, L., CW, M., . . . JP, N. (2026). Neoadjuvant therapy for left-sided resectable pancreatic ductal adenocarcinoma: Evidence-based shift or premature extrapolation? Hepatobiliary surgery and nutrition, 15(1), 15. https://doi.org/10.21037/hbsn-2025-587

Chicago Style (17th ed.) Citation

FG, Uzunoglu, Springfeld C, Peccerella T, Hank T, Loos M, Michalski CW, Hackert T, and Neoptolemos JP. "Neoadjuvant Therapy for Left-sided Resectable Pancreatic Ductal Adenocarcinoma: Evidence-based Shift or Premature Extrapolation?" Hepatobiliary Surgery and Nutrition 15, no. 1 (2026): 15. https://doi.org/10.21037/hbsn-2025-587.

MLA (9th ed.) Citation

FG, Uzunoglu, et al. "Neoadjuvant Therapy for Left-sided Resectable Pancreatic Ductal Adenocarcinoma: Evidence-based Shift or Premature Extrapolation?" Hepatobiliary Surgery and Nutrition, vol. 15, no. 1, 2026, p. 15, https://doi.org/10.21037/hbsn-2025-587.